Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing

Core Insights - Quest Diagnostics (DGX) has announced a collaboration with Epic to enhance laboratory testing experiences for healthcare providers and patients in the U.S. [1][9] Collaboration Details - The partnership, named Project Nova, is a multi-year initiative aimed at streamlining customer-facing processes across all EHR platforms by utilizing Epic's Diagnostic Enterprise system [2][9] - The implementation will focus on consolidating technologies to improve operational agility, efficiency, and quality, including account onboarding, lab ordering, results reporting, appointment scheduling, billing, and customer service [3] Patient Experience Enhancement - The initiative aims to enhance the patient experience through solutions like MyChart, which will provide greater transparency in health plan reimbursement and simplify appointment scheduling at Quest's 2,000 patient service centers across the U.S. [3][9] Industry Prospects - The global clinical laboratory tests market is projected to reach $213.04 billion by 2030, with a CAGR of 8.88% from 2025 to 2030, driven by rising life expectancy and increasing demand for diagnostic testing [4] Additional Updates - Haystack Oncology, a Quest Diagnostics company, has collaborated with the Rutgers Cancer Institute to evaluate a highly sensitive ctDNA MRD test for optimizing postoperative therapy in stage II/III non-small cell lung cancer patients [5] - Quest Diagnostics has also formed a joint venture with Corewell Health to expand access to innovative and affordable laboratory services in Michigan [6]